



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

difficult to make such estimates early in an outbreak,⁹ and it is clear that not all infections become cases and studies of many tiers of severity (deaths measured as a proportion of hospitalisations, notified cases and syndromic surveillance, and even potentially serosurveillance testing when available) will be needed to establish infection-fatality rates.

Ongoing modelling and surveillance should continue at the epicentre of the pandemic in mainland China to assess the effect of public health measures. However, attention must also move to the emerging foci outside of China, including Italy, Iran, and South Korea, to determine if the reproduction ratio might vary in different climates and sociological contexts. New foci of infection across different continents change the risk to global communities, as this coronavirus becomes a pandemic.

I declare no competing interests.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Emma McBryde
emma.mcbride@jcu.edu.au

Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, QLD 4814, Australia

- 1 Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; **395**: 565–74.
- 2 GISAIID: Genomic epidemiology of BetaCoV 2019–2020. <https://www.gisaid.org/epiflu-applications/next-sars-cov2-app/> (accessed Feb 26, 2020).
- 3 Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *N Engl J Med* 2020; published online Jan 30. DOI:10.1056/NEJMc2001468.
- 4 De Salazar PM, Niehus R, Taylor A, Buckee CO, Lipsitch M. Using predicted imports of 2019-nCoV cases to determine locations that may not be identifying all imported cases. *medRxiv* 2020; published online Feb 11. DOI:10.1101/2020.02.04.20020495 (preprint).
- 5 Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020; published online Jan 31. [https://doi.org/10.1016/S0140-6736\(20\)30260-9](https://doi.org/10.1016/S0140-6736(20)30260-9).
- 6 Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med* 2020; published online Feb 13. DOI:10.1093/jtm/taaa021.
- 7 Kucharski AJ, Russell TW, Diamond C, et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *Lancet Infect Dis* 2020; published online March 11. [https://doi.org/10.1016/S1473-3099\(20\)30144-4](https://doi.org/10.1016/S1473-3099(20)30144-4).
- 8 WHO. Coronavirus disease 2019 (COVID-19) situation report—29. Feb 19, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200218-sitrep-29-covid-19.pdf?sfvrsn=6262de9e_2 (accessed Feb 26, 2020).
- 9 Ghani AC, Donnelly CA, Cox DR, et al. Methods for estimating the case fatality ratio for a novel, emerging infectious disease. *Am J Epidemiol* 2005; **162**: 479–86.

Management of pregnant women infected with COVID-19

Since December, 2019, the outbreak of coronavirus disease 2019 (COVID-19), which originated in Wuhan, China, has become a global public health threat.¹ On Feb 28, 2020, WHO upgraded their assessment of the risk of spread and the risk of impact of COVID-19 to very high at global level. By March 10, 2020, 116 166 cases have been reported globally, causing 4088 deaths. The epidemic has spread to 118 countries around the world.²

With immunocompromised status and physiological adaptive changes during pregnancy, pregnant women could be more susceptible to COVID-19 infection than the general population. As COVID-19 is rapidly spreading, maternal management and fetal safety become a major concern, but there is scarce information of assessment and management of pregnant women infected with COVID-19, and the potential risk of vertical transmission is unclear. In *The Lancet Infectious Diseases*, Nan Yu and colleagues³ report the clinical features and obstetric and neonatal outcomes of pregnancy with COVID-19 pneumonia in Wuhan, China.

Seven pregnant women with COVID-19 pneumonia were assessed and the onset symptoms were similar to those reported in non-pregnant adults with COVID-19. All patients received oxygen therapy and antiviral treatment in isolation. All patients had caesarean section after consultation with a multidisciplinary team and the outcomes of the pregnant women and neonates were good. Three neonates were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and one was found to be infected with COVID-19 36 h after birth. The findings of the study provide some indications for clinical assessment and management of pregnant women with COVID-19, but questions remain on how to manage pregnant women infected with COVID-19.

As Yu and colleagues³ reported, five pregnant women were treated with steroids after caesarean section. Two were also treated with traditional Chinese medicine. However, no reliable evidence recommends any specific COVID-19 treatment for pregnant women. WHO guidance and some clinical evidence does not recommend the use of corticosteroids for COVID-19.^{4,5}



Published Online
March 24, 2020
[https://doi.org/10.1016/S1473-3099\(20\)30191-2](https://doi.org/10.1016/S1473-3099(20)30191-2)
See [Articles](#) page 553

Use of drugs in pregnant women needs to be on the basis of solid evidence. Clinical trials are needed to prove the effectiveness of drugs and the effects on the fetus to establish a standardised treatment for pregnant women with COVID-19. More evidence of the safety of traditional Chinese medicine is also warranted.

The time of delivery in the study was 37 weeks to 41 weeks plus 5 days, all by caesarean section. In cases of pregnant women with COVID-19, more evidence is needed to establish when to deliver and when caesarean sections should be recommended. Previous treatment experience has been inconclusive about which delivery method is safer in this patient population. Zhu and colleagues⁶ reported nine pregnant women with COVID-19. Seven of the women delivered their babies by cesarean section and two by vaginal delivery. All three neonates delivered vaginally (including two who were twins) had an Apgar score of at least 9 and negative nucleic acid test. Yudin and colleagues⁷ reported a pregnant woman with SARS at 31 weeks of gestation; the patient stayed for 21 days in the hospital and did not require intensive care admission or ventilatory support, and a healthy baby girl was delivered by vaginal birth. It is unknown whether vaginal delivery increases the infection risk. Further research is needed to assess the risk and to produce guidelines for delivery times and methods in patients with COVID-19.

As discussed in the study, although all mothers and infants showed good outcomes, all enrolled pregnant women were in the third trimester, and all had only mild symptoms. Hence, the effect of SARS-CoV-2 infection on the fetus in the first or second trimester or in patients with moderate to severe infection is unknown. As a previous study reported, SARS coronavirus infection during pregnancy might cause preterm birth, intrauterine growth restriction, intrauterine death, and neonatal death.⁸ Considering that the potential of SARS-CoV-2 to cause severe obstetric and neonatal adverse outcomes is unknown, rigorous screening of suspected cases during pregnancy and long-term follow-up of confirmed mothers and their neonates are needed.

In the study by Yu and colleagues,³ three neonates were tested for SARS-CoV-2, of whom two were negative. One neonate was positive, but the viral nucleic acid tests of the placenta and cord blood in this case were negative. At the end of follow-up, no pneumonia and other clinical symptoms and signs were reported in any of the

seven neonates. No reliable evidence has been provided in support of the possibility of vertical transmission of COVID-19 infection from mother to baby. The outcomes are consistent with previous reports.^{9,10} But all these studies only assessed a small number of cases. Future studies should include a larger number of samples across multiple centres to establish whether vertical transmission can occur between mother and child.

Yu and colleagues³ report of the clinical features and obstetric and neonatal outcomes of pregnant women with COVID-19 provides a reference for clinical assessment and management of this patient population. However, understanding of SARS-CoV-2, especially the effect on pregnant women and neonates, is still insufficient. We need to further strengthen research to provide an evidence-based foundation for the medical management of pregnant patients with COVID-19.

We declare no competing interests. We provided the management and follow-up information for the neonate positive for SARS-CoV-2 described in the paper by Yu and colleagues; we were not involved in the management of the pregnant women described in the paper.

Yongwen Luo, *Kai Yin
yinkai512@126.com

Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (YL); Department of Burns and Plastic Surgery, Beijing Jishuitan Hospital, Beijing 100035, China (KY)

- 1 Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020; published online Jan 29. DOI:10.1056/NEJMoa2001316.
- 2 WHO. Coronavirus disease 2019 (COVID-2019) situation report 46. March 6, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_2 (accessed March 6, 2020).
- 3 Yu N, Wei L, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet* 2020; published online Mar 24. [https://doi.org/10.1016/S1473-3099\(20\)30176-6](https://doi.org/10.1016/S1473-3099(20)30176-6).
- 4 WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Jan 28, 2020. [https://www.who.int/publications-detail/clinical-management-of-severeacute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-issuspected](https://www.who.int/publications-detail/clinical-management-of-severeacute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-issuspected) (accessed March 6, 2020).
- 5 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020; **395**: 473-75.
- 6 Zhu H P, L W, Cheng Z F, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr* 2020; published online Feb 10. DOI:10.21037/tp.2020.02.06.
- 7 Yudin MH, Steele DM, Sgro MD, Read SE, Kopplin P, Gough KA. Severe acute respiratory syndrome in pregnancy. *Obstet Gynecol* 2005; **105**: 124-27.
- 8 Lam CM, Wong SF, Leung TN, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. *BJOG* 2004; **111**: 771-74.
- 9 Chen S, Huang B, Luo DJ, et al. Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases. *Zhonghua Bing Li Xue Za Zhi* 2020; **49**: e005 (in Chinese).
- 10 Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020; **395**: 809-15.